Current treatment decisions for sentinel lymph node biopsy referral are made based on clinicopathologic factors such as patient’s age, Breslow thickness and ulceration. However, these variables do not always provide complete insights of the melanoma.
With the Merlin Test, it is possible to take a deeper look into the biology of your melanoma by analyzing the expression of 8 specific genes involved in processes related to cancer metastasis and melanosome biogenesis – alongside the clinicopathologic variables patient’s age and Breslow thickness.
The Merlin Test helps in identifying primary cutaneous melanoma patients who have a low risk of having nodal metastasis and may therefore forgo a sentinel lymph node biopsy procedure.
The Merlin Test has been developed in partnership by SkylineDx and the Mayo Clinic (USA) and has been validated in multiple multicenter clinical trials in the United States and in Europe.